These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 36873421)

  • 1. Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease.
    Balcar L; Krawanja J; Scheiner B; Paternostro R; Simbrunner B; Semmler G; Jachs M; Hartl L; Stättermayer AF; Schwabl P; Pinter M; Szekeres T; Trauner M; Reiberger T; Mandorfer M
    JHEP Rep; 2023 Apr; 5(4):100682. PubMed ID: 36873421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD.
    Scheiner B; Balcar L; Nussbaumer RJ; Weinzierl J; Paternostro R; Simbrunner B; Hartl L; Jachs M; Bauer D; Stättermayer AF; Semmler G; Pinter M; Ay C; Quehenberger P; Trauner M; Reiberger T; Lisman T; Mandorfer M
    J Hepatol; 2022 May; 76(5):1090-1099. PubMed ID: 35066090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An impaired pituitary-adrenal signalling axis in stable cirrhosis is linked to worse prognosis.
    Hartl L; Simbrunner B; Jachs M; Wolf P; Bauer DJM; Scheiner B; Balcar L; Semmler G; Schwarz M; Marculescu R; Trauner M; Mandorfer M; Reiberger T
    JHEP Rep; 2023 Aug; 5(8):100789. PubMed ID: 37484210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower free triiodothyronine (fT3) levels in cirrhosis are linked to systemic inflammation, higher risk of acute-on-chronic liver failure, and mortality.
    Hartl L; Simbrunner B; Jachs M; Wolf P; Bauer DJM; Scheiner B; Balcar L; Semmler G; Schwarz M; Marculescu R; Dannenberg V; Trauner M; Mandorfer M; Reiberger T
    JHEP Rep; 2024 Jan; 6(1):100954. PubMed ID: 38125301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality.
    Costa D; Simbrunner B; Jachs M; Hartl L; Bauer D; Paternostro R; Schwabl P; Scheiner B; Stättermayer AF; Pinter M; Trauner M; Mandorfer M; Reiberger T
    J Hepatol; 2021 Apr; 74(4):819-828. PubMed ID: 33075344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death.
    Jachs M; Hartl L; Simbrunner B; Bauer D; Paternostro R; Scheiner B; Schwabl P; Stättermayer AF; Pinter M; Eigenbauer E; Quehenberger P; Trauner M; Reiberger T; Mandorfer M
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1362-1373.e6. PubMed ID: 34256145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-1 antitrypsin Pi∗Z allele is an independent risk factor for liver transplantation and death in patients with advanced chronic liver disease.
    Balcar L; Scheiner B; Urheu M; Weinberger P; Paternostro R; Simbrunner B; Hartl L; Jachs M; Bauer D; Semmler G; Willheim C; Pinter M; Ferenci P; Trauner M; Reiberger T; Stättermayer AF; Mandorfer M
    JHEP Rep; 2022 Nov; 4(11):100562. PubMed ID: 36176936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD.
    Paternostro R; Kwanten WJ; Hofer BS; Semmler G; Bagdadi A; Luzko I; Hernández-Gea V; Graupera I; García-Pagán JC; Saltini D; Indulti F; Schepis F; Moga L; Rautou PE; Llop E; Téllez L; Albillos A; Fortea JI; Puente A; Tosetti G; Primignani M; Zipprich A; Vuille-Lessard E; Berzigotti A; Taru MG; Taru V; Procopet B; Jansen C; Praktiknjo M; Gu W; Trebicka J; Ibanez-Samaniego L; Bañares R; Rivera-Esteban J; Pericas JM; Genesca J; Alvarado E; Villanueva C; Larrue H; Bureau C; Laleman W; Ardevol A; Masnou H; Vanwolleghem T; Trauner M; Mandorfer M; Francque S; Reiberger T;
    J Hepatol; 2024 Nov; 81(5):827-836. PubMed ID: 38823501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Von Willebrand factor for outcome prediction within different clinical stages of advanced chronic liver disease.
    Dominik N; Scheiner B; Zanetto A; Balcar L; Semmler G; Campello E; Schwarz M; Paternostro R; Simbrunner B; Hofer BS; Stättermayer AF; Pinter M; Trauner M; Quehenberger P; Simioni P; Reiberger T; Mandorfer M
    Aliment Pharmacol Ther; 2024 Jun; 59(11):1376-1386. PubMed ID: 38482706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver disease.
    Pomej K; Scheiner B; Balcar L; Nussbaumer RJ; Weinzierl J; Paternostro R; Simbrunner B; Bauer D; Pereyra D; Starlinger P; Stättermayer AF; Pinter M; Trauner M; Quehenberger P; Reiberger T; Mandorfer M
    Dig Liver Dis; 2022 Oct; 54(10):1376-1384. PubMed ID: 35871985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event.
    Balcar L; Tonon M; Semmler G; Calvino V; Hartl L; Incicco S; Jachs M; Bauer D; Hofer BS; Gambino CG; Accetta A; Brocca A; Trauner M; Mandorfer M; Piano S; Reiberger T;
    JHEP Rep; 2022 Aug; 4(8):100513. PubMed ID: 35845294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High histamine levels are associated with acute-on-chronic liver failure and liver-related death in patients with advanced chronic liver disease.
    Schwarz M; Simbrunner B; Jachs M; Hartl L; Balcar L; Bauer DJM; Semmler G; Hofer BS; Scheiner B; Pinter M; Stättermayer AF; Trauner M; Reiberger T; Mandorfer M
    Liver Int; 2024 Nov; 44(11):2904-2914. PubMed ID: 39136222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis.
    Tranah TH; Ballester MP; Carbonell-Asins JA; Ampuero J; Alexandrino G; Caracostea A; Sánchez-Torrijos Y; Thomsen KL; Kerbert AJC; Capilla-Lozano M; Romero-Gómez M; Escudero-García D; Montoliu C; Jalan R; Shawcross DL
    J Hepatol; 2022 Dec; 77(6):1554-1563. PubMed ID: 35872326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
    Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
    Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome.
    Simbrunner B; Villesen IF; Scheiner B; Paternostro R; Schwabl P; Stättermayer AF; Marculescu R; Pinter M; Quehenberger P; Trauner M; Karsdal M; Lisman T; Reiberger T; Leeming DJ; Mandorfer M
    Hepatol Int; 2023 Dec; 17(6):1532-1544. PubMed ID: 37605068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alcohol Abstinence Improves Prognosis Across All Stages of Portal Hypertension in Alcohol-Related Cirrhosis.
    Hofer BS; Simbrunner B; Hartl L; Jachs M; Bauer DJM; Balcar L; Paternostro R; Schwabl P; Semmler G; Scheiner B; Staettermayer AF; Trauner M; Mandorfer M; Reiberger T
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2308-2317.e7. PubMed ID: 36481475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysregulated biomarkers of innate and adaptive immunity predict infections and disease progression in cirrhosis.
    Simbrunner B; Hartl L; Jachs M; Bauer DJM; Scheiner B; Hofer BS; Stättermayer AF; Marculescu R; Trauner M; Mandorfer M; Reiberger T
    JHEP Rep; 2023 May; 5(5):100712. PubMed ID: 37035457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Balance between macrophage migration inhibitory factor and sCD74 predicts outcome in patients with acute decompensation of cirrhosis.
    Wirtz TH; Reuken PA; Jansen C; Fischer P; Bergmann I; Backhaus C; Emontzpohl C; Reißing J; Brandt EF; Koenen MT; Schneider KM; Schierwagen R; Brol MJ; Chang J; Zimmermann HW; Köse-Vogel N; Eggermann T; Kurth I; Stoppe C; Bucala R; Bernhagen J; Praktiknjo M; Stallmach A; Trautwein C; Trebicka J; Bruns T; Berres ML
    JHEP Rep; 2021 Apr; 3(2):100221. PubMed ID: 33659891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease.
    Simbrunner B; Villesen IF; Königshofer P; Scheiner B; Bauer D; Paternostro R; Schwabl P; Timelthaler G; Ramazanova D; Wöran K; Stift J; Eigenbauer E; Stättermayer AF; Marculescu R; Pinter M; Møller S; Trauner M; Karsdal M; Leeming DJ; Reiberger T; Mandorfer M
    Liver Int; 2022 Nov; 42(11):2501-2512. PubMed ID: 35822301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes.
    Jachs M; Hartl L; Schaufler D; Desbalmes C; Simbrunner B; Eigenbauer E; Bauer DJM; Paternostro R; Schwabl P; Scheiner B; Bucsics T; Stättermayer AF; Pinter M; Trauner M; Mandorfer M; Reiberger T
    Gut; 2021 Sep; 70(9):1758-1767. PubMed ID: 33199442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.